Phase 1 Study to Evaluate [18F]ACI-15916 As a Potential PET Radioligand for Imaging Α-synuclein Deposits in the Brain of Patients with Suspected Α-synuclein Pathology Compared with Healthy Volunteers
Latest Information Update: 14 Apr 2025
At a glance
- Drugs ACI 15916 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors AC Immune
- 28 Mar 2025 New trial record
- 13 Mar 2025 According to AC Immune media release, phase 1 data readout is expected in second half of 2025.